Profitability Climbs on Strength of Distribution Strategy and
Recently Introduced Products WESTFORD, Mass., May 1
/PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading
developer and manufacturer of a broad array of light-based
aesthetic treatment systems, today announced financial results for
the quarter ended March 31, 2007. First Quarter 2007 Financial
Results Revenues increased 52% to a record $26.1 million from $17.1
million for the first quarter of 2006. Gross profit margin
increased 890 basis points to 62.0% of total revenues compared with
53.1% for the same period in 2006. First quarter 2007 net income
was $2.1 million, or $0.17 per diluted share, which includes
approximately $1.4 million in stock-based compensation expense.
This compares with net income of $0.6 million, or $0.05 per diluted
share, in the first quarter of 2006. Results for the first quarter
of 2006 included approximately $0.3 million in stock-based
compensation expense and $1.1 million in expenses relating to the
write-down of inventory and uncollectible accounts receivable
related to the Company's legacy relationship with Sona MedSpa
International. Non-GAAP net income, which excludes the stock-based
compensation expense and for 2006, expenses relating to Sona
MedSpa, was $3.1 million, or $0.25 per diluted share, for the first
quarter of 2007 compared with $1.5 million, or $0.12 per diluted
share, in the first quarter of 2006. Please refer to the financial
reconciliations included in this news release for a reconciliation
of GAAP results to Non-GAAP results for the three months ended
March 31, 2007 and 2006. "Our first-quarter financial results
highlight the strength of our broad product line, including our
recently introduced innovative flagship systems such as the
Affirm(TM) Anti-Aging Workstation and the Smartlipo(TM)
LaserBodySculpting system, coupled with the continued momentum of
our global distribution strategy and the growing demand for bundled
product solutions," said President and Chief Executive Officer
Michael Davin. "Customers increasingly are turning to Cynosure for
comprehensive, multi-energy-source solutions for a broad range of
light-based aesthetic procedures, from hair removal to skin
rejuvenation to laser lipolysis. In the first quarter, we
capitalized on a number of cross-selling opportunities by bundling
our products to provide customers with a total solution for their
aesthetic practice." "Our installed base of Affirm systems
continues to grow worldwide, and we are very pleased with its
performance," Davin said. "The Affirm system, which includes a
disposable micro lens array, contributed to the continued expansion
of our overall gross margin to 62 percent in the quarter. In
February, we announced the addition of a new 1320nm wavelength
Nd:YAG laser to the Affirm workstation. The Affirm is one of the
industry's most comprehensive solutions for anti-aging
applications, including skin rejuvenation, treatments for wrinkles,
discoloration and tissue tightening as a result of tissue
coagulation. We are pleased with the market's response to this
total anti- aging solution workstation." "Smartlipo, our
proprietary LaserBodySculpting workstation, also performed well in
the quarter contributing to the 59 percent increase we realized in
our laser system revenue," said Davin. "During the quarter, we
completed the hiring of a 10-person surgical specialty sales force
to market and sell Smartlipo in North America and we signed a
four-state distribution agreement with Eclipse Medical Ltd. In
addition we have established 11 Smartlipo physician training sites
throughout North America. In just a few months since its
introduction, we believe the minimally invasive Smartlipo is
becoming the standard for consumers looking for a highly targeted
solution to treat localized areas of unwanted fat." First-Quarter
Highlights - Cynosure selected Depilite Medic Spa Equipment Corp.
as the exclusive distributor of Cynosure's Affirm Anti-Aging
Workstation and the Elite(TM) Aesthetic Workstation in Mexico,
Argentina, Colombia, Honduras and Peru. Depilite currently operates
more than 100 branches located in seven countries in North America,
Europe and Latin America. - Cynosure unveiled a new deep-heating,
1320nm wavelength Nd:YAG laser for its Affirm workstation. The new
laser complements the range of treatment options now possible on
the Affirm workstation to include tissue tightening as a result of
tissue coagulation, in addition to fractional micro-rejuvenation
and discoloration. - Cynosure's Affirm workstation was selected as
the fractional anti-aging technology of choice by American Laser
Centers. American Laser Centers operates more than 150 U.S. centers
focusing on laser hair removal, skin rejuvenation and cellulite
reduction therapy. - Cynosure signed an exclusive three-year
distribution agreement with Eclipse Medical Ltd. for distribution
of Cynosure's Smartlipo laser lipolysis system in Texas, Louisiana,
Arkansas and Oklahoma. Business Outlook "Cynosure is off to an
outstanding start in 2007, and we are excited about the continued
potential of our newest flagship products - Affirm and Smartlipo,"
Davin concluded. "Industry trends continue to support our growth as
we believe consumer demand for aesthetic procedures will continue
to steadily rise. We believe that our strong product platform and
comprehensive distribution strategy are competitive advantages that
will help sustain our momentum in the quarters ahead." Use of
Non-GAAP Financial Measures To supplement Cynosure's consolidated
financial statements presented in accordance with GAAP, this press
release includes the following measures defined as non-GAAP
financial measures by the SEC: non-GAAP net income and non-GAAP
diluted earnings per share. The presentation of this financial
information is not intended to be considered in isolation or as a
substitute for the financial information prepared and presented in
accordance with GAAP. In addition, the non-GAAP financial measures
included in this press release may be different from, and therefore
not comparable to, similar measures used by other companies.
Although certain non-GAAP financial measures used in this release
exclude the accounting treatment of stock-based compensation, these
non-GAAP measures should not be relied upon independently, as they
ignore the contribution to our operating results that is generated
by the incentive and compensation effects of the underlying
stock-based compensation programs. For more information on these
non-GAAP financial measures, please see the non-GAAP data included
at the end of this release. This data has more details of the GAAP
financial measures that are most directly comparable to non-GAAP
financial measures and the related reconciliations between these
financial measures. Cynosure's management believes that these
non-GAAP financial measures provide meaningful supplemental
information regarding our performance by excluding certain expenses
and expenditures that may not be indicative of our core business
operating results. Cynosure believes that both management and
investors benefit from referring to these non-GAAP financial
measures in assessing Cynosure's performance and when planning,
forecasting and analyzing future periods. These non-GAAP financial
measures also facilitate management's internal comparisons to
Cynosure's historical performance and our competitors' operating
results. Cynosure believes that these non-GAAP measures are useful
to investors in allowing for greater transparency with respect to
supplemental information used by management in its financial and
operational decision making. Conference Call Cynosure will host a
conference call for investors today at 9:00 a.m. ET. On the call,
Michael Davin and Timothy Baker, the company's executive vice
president and chief financial officer, will discuss the
first-quarter 2007 financial results, provide a business update and
discuss the company's growth strategy. Those who wish to listen to
the conference call webcast should visit the "Investor Relations"
section of the company's website at http://www.cynosure.com/. The
live call also can be accessed by dialing (800) 289-0569 or (913)
981-5542 (confirmation code: 1889045). If you are unable to listen
to the live call, the webcast will be archived on the company's
website. About Cynosure, Inc. Cynosure, Inc. develops and markets
aesthetic treatment systems that are used by physicians and other
practitioners to perform non-invasive and minimally invasive
procedures to remove hair, treat vascular lesions, rejuvenate skin
through the treatment of shallow vascular and pigmented lesions,
laser lipolysis and temporarily reduce the appearance of cellulite.
Cynosure's products include a broad range of laser and other
light-based energy sources, including Alexandrite, pulsed dye,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Safe
Harbor Any statements in this press release about future
expectations, plans and prospects for Cynosure, Inc., including
statements about the company's expectations and future financial
performance, as well as other statements containing the words
"believes," "anticipates," "plans," "expects," "will" and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including Cynosure's history of operating losses, its
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, timing of
the company's international launch of the Affirm system, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K, which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Consolidated Statements of Income (In
thousands, except per share data) Three Months Ended March 31, 2007
2006 (unaudited) Revenues $26,077 $17,139 Cost of revenues 9,922
8,032 Gross profit 16,155 9,107 Operating expenses Selling and
marketing 9,262 5,458 Research and development 1,723 1,209 General
and administrative 2,295 2,146 Total operating expenses 13,280
8,813 Income from operations 2,875 294 Interest income, net 505 652
Other income, net 56 130 Income before income taxes 3,436 1,076
Income tax provision 1,318 436 Minority interest in net income of
subsidiary - 14 Net income $2,118 $626 Diluted net income per share
$0.17 $0.05 Diluted weighted average shares outstanding 12,374
12,178 Basic net income per share $0.19 $0.06 Basic weighted
average shares outstanding 11,345 11,031 Non-GAAP data Gross Profit
$16,155 $9,107 Sona - inventory writedown - 667 Stock-based
compensation 98 6 Non-GAAP Gross Profit 16,253 9,780 Operating
Expenses: 13,280 8,813 Sona - provision for doubtful account -
(463) Stock-based compensation (1,252) (292) Non-GAAP Operating
Expenses 12,028 8,058 Non-GAAP Income from Operations: 4,225 1,722
Interest income, net and other income, net 561 782 Non-GAAP Income
before income taxes 4,786 2,504 Non-GAAP provision for income taxes
1,723 989 Minority Interest - 14 Non-GAAP Net income $3,063 $1,501
Non-GAAP diluted net income per share $0.25 $0.12 Diluted weighted
average shares outstanding 12,374 12,178 Condensed Consolidated
Balance Sheet (In thousands) March 31, December 31, 2007 2006
(unaudited) Assets: Cash, cash equivalents and marketable
securities $62,164 $57,246 Accounts receivable, net 20,418 19,871
Amounts due from related parties 346 335 Inventories 19,267 17,624
Deferred tax asset, current portion 2,575 2,604 Prepaid expenses
and other current assets 3,668 4,977 Total current assets 108,438
102,657 Property and equipment, net 6,145 5,662 Other noncurrent
assets 1,242 1,247 Total assets $115,825 $109,566 Liabilities and
stockholders' equity: Accounts payable and accrued expenses $16,398
$17,063 Amounts due to related parties 2,131 1,052 Short-term loan
- 167 Deferred revenue 3,651 3,476 Capital lease obligations 452
439 Total current liabilities 22,632 22,197 Capital lease
obligations, net of current portion 1,021 1,069 Deferred revenue,
net of current portion 289 311 Other long-term liabilities 136 119
Total stockholders' equity 91,747 85,870 Total liabilities and
stockholders' equity $115,825 $109,566 DATASOURCE: Cynosure, Inc.
CONTACT: Scott Solomon, Vice President, Sharon Merrill Associates,
Inc., +1-617-542-5300, , for Cynosure, Inc. Web site:
http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024